论文部分内容阅读
以大麻素受体1阻滞剂作为减肥药物的计划被终止了,这类曾被寄予厚望的药物带着遗憾止步于此。如何汲取其中的教训,促进此后同类药物的开发,需要业界思考。
The plan to use cannabinoid receptor 1 blockers as a weight-loss drug was discontinued, and regretted halt to such promising drugs. How to learn the lessons learned and promote the development of similar drugs afterwards need the industry to think.